首次人体无创初诊方法:18F-氟达拉滨与L-[甲基-11C]蛋氨酸PET鉴别原发性中枢神经系统淋巴瘤与胶质母细胞瘤
本研究纳入未经治疗的PCNSL(n=8)、经皮质类固醇治疗的PCNSL(PCNSLh,n=10)和GBM(n=13)患者,采用11C-MET和18F-FLUDA PET/CT比较摄取参数。11C-MET在各组间无显著差异;18F-FLUDA动态摄取模式不同,R FLUDA 2和R FLUDA 3整合注射后首60秒早期摄取,提供100%特异度和灵敏度。作者认为18F-FLUDA可能是有前景的显像剂,但皮质类固醇预处理可能削弱其鉴别诊断能力。
要点
- 11C-MET在PCNSL、PCNSLh和GBM间摄取无显著差异。
- 18F-FLUDA在GBM早期达峰后随时间下降,PCNSL持续上升,PCNSLh居中。
- R FLUDA 2和R FLUDA 3整合首60秒摄取,特异度和灵敏度均为100%。
核心结论
- 18F-FLUDA可能是有前景的放射性药物,用于鉴别PCNSL与其他恶性肿瘤。
- 皮质类固醇预处理可能削弱18F-FLUDA的鉴别诊断能力。
- 18F-FLUDA的诊断作用及其在PCNSL治疗策略制定和疗效评估中的潜力有待进一步研究。
研究设计与样本
- 首次人体研究,纳入未经治疗的PCNSL患者8例、经皮质类固醇治疗的PCNSL患者10例和GBM患者13例。
- 所有患者接受常规MRI及11C-MET和18F-FLUDA PET/CT检查。
主要发现
- 11C-MET摄取在PCNSL、PCNSLh和GBM三组间无显著差异。
- 18F-FLUDA动态摄取在GBM中早期达峰后随时间下降,在PCNSL中随时间持续上升,PCNSLh呈中间值。
- R FLUDA 2和R FLUDA 3整合注射后首60秒早期摄取,提供100%特异度和灵敏度。
关键数值与推荐
- 主要参数为11C-MET采集前30分钟的SUV T和T/N比值,以及18F-FLUDA注射后3个不同时间的相应参数。
- 早期18F-FLUDA摄取取注射后第一分钟内的值,并与后期摄取组合得到R FLUDA 2和R FLUDA 3比值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study sought to assess 18 F-fludarabine ( 18 F-FLUDA) PET/CT's ability in differentiating primary central nervous system lymphomas (PCNSLs) from glioblastoma multiformes (GBMs). PATIENTS AND METHODS: Patients harboring either PCNSL (n = 8) before any treatment, PCNSL treated using corticosteroids (PCNSLh; n = 10), or GBM (n = 13) were investigated with conventional MRI and PET/CT, using 11 C-MET and 18 F-FLUDA. The main parameters measured with each tracer were SUV T and T/N ratios for the first 30 minutes of 11 C-MET acquisition, as well as at 3 different times after 18 F-FLUDA injection. The early 18 F-FLUDA uptake within the first minute of injection was equally considered, whereas this parameter was combined with the later uptakes to obtain R FLUDA 2 and R FLUDA 3 ratios. RESULTS: No significant differences in 11 C-MET uptakes were observed among PCNSL, PCNSLh, and GBM. With 18 F-FLUDA, a clear difference in dynamic GBM uptake was observed, which decreased over time after an early maximum, as compared with that of PCNSL, which steadily increased over time, PCNSLh exhibiting intermediate values. The most discriminative parameters consisting of R FLUDA 2 and R FLUDA 3 integrated the early tracer uptake (first 60 seconds), thereby provided 100% specificity and sensitivity. CONCLUSIONS: 18 F-FLUDA was shown to likely be a promising radiopharmaceutical for differentiating PCNSL from other malignancies, although a pretreatment with corticosteroids might compromise this differential diagnostic ability. The diagnostic role of 18 F-FLUDA should be further investigating, along with its potential of defining therapeutic strategies in patients with PCNSL, while assessing the treatments' effectiveness.
引用
- Postnov A, Toutain J, Pronin I, et al. First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18 F-Fludarabine and l -[methyl- 11 C]Methionine. Clin Nucl Med. 2022. PMID: 35485864. doi:10.1097/RLU.0000000000004238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。